Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt N/A
SGMO's Cash to Debt is ranked higher than
98% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. SGMO: N/A )
Ranked among companies with meaningful Cash to Debt only.
SGMO' s Cash to Debt Range Over the Past 10 Years
Min: 1.71  Med: 10000.00 Max: No Debt
Current: N/A
Equity to Asset 0.89
SGMO's Equity to Asset is ranked higher than
80% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SGMO: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
SGMO' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.88 Max: 0.99
Current: 0.89
0.39
0.99
Interest Coverage No Debt
SGMO's Interest Coverage is ranked higher than
97% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGMO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SGMO' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 5.76
M-Score: -3.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -118.51
SGMO's Operating margin (%) is ranked lower than
54% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. SGMO: -118.51 )
Ranked among companies with meaningful Operating margin (%) only.
SGMO' s Operating margin (%) Range Over the Past 10 Years
Min: -553.46  Med: -138.31 Max: -58.38
Current: -118.51
-553.46
-58.38
Net-margin (%) -102.94
SGMO's Net-margin (%) is ranked lower than
53% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. SGMO: -102.94 )
Ranked among companies with meaningful Net-margin (%) only.
SGMO' s Net-margin (%) Range Over the Past 10 Years
Min: -535.14  Med: -134.80 Max: -57.59
Current: -102.94
-535.14
-57.59
ROE (%) -20.15
SGMO's ROE (%) is ranked higher than
64% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. SGMO: -20.15 )
Ranked among companies with meaningful ROE (%) only.
SGMO' s ROE (%) Range Over the Past 10 Years
Min: -52.56  Med: -36.72 Max: -16.09
Current: -20.15
-52.56
-16.09
ROA (%) -17.52
SGMO's ROA (%) is ranked higher than
65% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. SGMO: -17.52 )
Ranked among companies with meaningful ROA (%) only.
SGMO' s ROA (%) Range Over the Past 10 Years
Min: -47.56  Med: -31.26 Max: -13.76
Current: -17.52
-47.56
-13.76
ROC (Joel Greenblatt) (%) -2281.95
SGMO's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. SGMO: -2281.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGMO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3614.47  Med: -1833.88 Max: -1066.04
Current: -2281.95
-3614.47
-1066.04
Revenue Growth (3Y)(%) 50.40
SGMO's Revenue Growth (3Y)(%) is ranked higher than
92% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SGMO: 50.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGMO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -38  Med: -1.90 Max: 68.7
Current: 50.4
-38
68.7
EBITDA Growth (3Y)(%) -17.70
SGMO's EBITDA Growth (3Y)(%) is ranked lower than
68% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. SGMO: -17.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGMO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -23.7  Med: 1.15 Max: 106.7
Current: -17.7
-23.7
106.7
EPS Growth (3Y)(%) -17.70
SGMO's EPS Growth (3Y)(%) is ranked lower than
66% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SGMO: -17.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGMO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.9  Med: -1.50 Max: 184.4
Current: -17.7
-24.9
184.4
» SGMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SGMO Guru Trades in Q1 2015

Steven Cohen 196,100 sh (+24.11%)
First Eagle Investment 559,780 sh (unchged)
First Eagle Investment 4,017 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2015

SGMO Guru Trades in Q2 2015

Jim Simons 107,697 sh (New)
Joel Greenblatt 30,334 sh (New)
Steven Cohen 320,300 sh (+63.34%)
First Eagle Investment 4,017 sh (unchged)
First Eagle Investment Sold Out
» More
Q3 2015

SGMO Guru Trades in Q3 2015

Chuck Royce 212,100 sh (New)
First Eagle Investment 200,000 sh (New)
Jim Simons 486,352 sh (+351.59%)
First Eagle Investment 6,517 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 28,300 sh (-91.16%)
» More
Q4 2015

SGMO Guru Trades in Q4 2015

Chuck Royce 312,100 sh (+47.15%)
» More
» Details

Insider Trades

Latest Guru Trades with SGMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 0.34
SGMO's Forward P/E is ranked higher than
99% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.58 vs. SGMO: 0.34 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.79
SGMO's P/B is ranked higher than
67% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. SGMO: 1.79 )
Ranked among companies with meaningful P/B only.
SGMO' s P/B Range Over the Past 10 Years
Min: 1.48  Med: 4.38 Max: 11.1
Current: 1.79
1.48
11.1
P/S 7.49
SGMO's P/S is ranked higher than
56% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. SGMO: 7.49 )
Ranked among companies with meaningful P/S only.
SGMO' s P/S Range Over the Past 10 Years
Min: 4.76  Med: 21.27 Max: 129.75
Current: 7.49
4.76
129.75
Current Ratio 10.29
SGMO's Current Ratio is ranked higher than
75% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. SGMO: 10.29 )
Ranked among companies with meaningful Current Ratio only.
SGMO' s Current Ratio Range Over the Past 10 Years
Min: 5.06  Med: 12.08 Max: 55.31
Current: 10.29
5.06
55.31
Quick Ratio 10.29
SGMO's Quick Ratio is ranked higher than
75% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SGMO: 10.29 )
Ranked among companies with meaningful Quick Ratio only.
SGMO' s Quick Ratio Range Over the Past 10 Years
Min: 5.06  Med: 12.08 Max: 55.31
Current: 10.29
5.06
55.31
Days Sales Outstanding 64.66
SGMO's Days Sales Outstanding is ranked lower than
62% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. SGMO: 64.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.14  Med: 27.53 Max: 142.68
Current: 64.66
1.14
142.68

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.78
SGMO's Price/Tangible Book is ranked higher than
78% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SGMO: 1.78 )
Ranked among companies with meaningful Price/Tangible Book only.
SGMO' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.89  Med: 3.85 Max: 12.58
Current: 1.78
0.89
12.58
Price/Median PS Value 0.36
SGMO's Price/Median PS Value is ranked higher than
84% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. SGMO: 0.36 )
Ranked among companies with meaningful Price/Median PS Value only.
SGMO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.3  Med: 1.25 Max: 5.52
Current: 0.36
0.3
5.52
Earnings Yield (Greenblatt) (%) -23.55
SGMO's Earnings Yield (Greenblatt) (%) is ranked lower than
68% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. SGMO: -23.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGMO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -24.36  Med: 0.00 Max: 0
Current: -23.55
-24.36
0

More Statistics

Revenue(Mil) $43
EPS $ -0.44
Beta2.58
Short Percentage of Float15.19%
52-Week Range $4.69 - 19.25
Shares Outstanding(Mil)70.05

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 25 24 44
EPS($) -0.64 -0.70 -0.60
EPS without NRI($) -0.64 -0.70 -0.60

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GBY.Germany, SGMO.Switzerland, 0R1D.UK,
Sangamo BioSciences Inc was incorporated in June 1995 in the state of Delaware. It is a clinical stage biopharmaceutical that company engaged in the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. The Company is engaged in the development of novel human therapeutics and is building a pipeline of ZFP Therapeutics. Its ZFP Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is the first therapeutic application of its ZFN technology and is being evaluated in an ongoing Phase 2 and two Phase 1/2 clinical trials. It has preclinical ZFP Therapeutic development programs in hemophilia and Parkinsons disease. In addition, it has research stage programs in other monogenic diseases; genetic conditions that result from a defect in a single gene, including hemoglobinopathies such as sickle cell anemia, lysosomal storage diseases and certain immunodeficiencies. On 8 January 2014, the Company has a collaborative partnership with Biogen Idec Inc.to research, develop and commercialize our preclinical ZFP Therapeutic development program, in hemoglobinopathies, and targeting sickle cell disease (SCD) and beta-thalassemia. It has a license agreement with the research reagent company Sigma-Aldrich Corporation (Sigma). Sigma has the exclusive rights to develop and market high value laboratory research reagents based upon its ZFP technology as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-derived gene editing tools under the trademark CompoZr and is selling transgenic animals through its SAGETM Labs business unit. The Company has a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, it has provided DAS with access to its ZFP technology and the exclusive rights to use it to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. DAS markets its ZFN technology under the trademark EXZACTTM Precision Technology. The Company has retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into human or animals for diagnostic, therapeutic, or prophylactic purposes. It faces competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies; for establishing relationships with academic and research institutions; and for licenses to proprietary technology. Its therapeutic or pharmaceutical products undergoes rigorous preclinical testing and clinical trials in humans and an extensive regulatory clearance process implemented by the U.S. Food and Drug Administration (FDA) under the federal Food, Drug and Cosmetic Act.
» More Articles for NAS:SGMO

Headlines

Articles On GuruFocus.com
Biogen or Bluebird: Which Will Lead in SCD? Apr 30 2015 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 03 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
Edited Transcript of SGMO earnings conference call or presentation 9-Feb-16 10:00pm GMT Feb 10 2016
Sangamo reports 4Q loss Feb 09 2016
Sangamo reports 4Q loss Feb 09 2016
SANGAMO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 09 2016
4:08 pm Sangamo BioSci reports EPS in-line, beats on revs; guides FY16 revs below consensus Feb 09 2016
Sangamo BioSciences Reports Fourth Quarter And Full Year 2015 Financial Results Feb 09 2016
Q4 2015 Sangamo BioSciences Inc Earnings Release - After Market Close Feb 09 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated... Feb 08 2016
Sangamo BioSciences Announces Presentation At The Leerink Partners 5th Annual Global Healthcare... Feb 04 2016
Sangamo BioSciences Announces Fourth Quarter And Full Year 2015 Conference Call And Webcast Feb 02 2016
Weird Science: 4 Healthcare And Medical Device Companies Developing Futuristic Technologies In 2016 Jan 29 2016
Sangamo Biosciences (SGMO) Worth a Look: Stock Up 9.2% Jan 13 2016
Sangamo BioSciences Highlights 2016 Catalysts at the 34th Annual J.P. Morgan Healthcare Conference Jan 11 2016
Sangamo BioSciences Highlights 2016 Catalysts at the 34th Annual J.P. Morgan Healthcare Conference Jan 11 2016
Sangamo BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : January 7, 2016 Jan 07 2016
Sangamo BioSciences Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference Jan 05 2016
Sangamo BioSciences Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference Jan 05 2016
Every Biotech Catalyst Wedbush Is Watching In 2016 Jan 02 2016
Timing is Crucial, Upside Analysis -- Analyst Notes on American Superconductor, Beazer Homes USA,... Dec 22 2015
Traders Look to Upside - Featured Research on HMS Holdings, Beazer Homes, Gray Television, and... Dec 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK